In March 2008, CYTOGEN Corporation was acquired by UK firm EUSA Pharma Inc. Cytogen Corporation is a product-driven, oncology-focused biopharmaceutical company. The Company markets two proprietary and licensed oncology products: ProstaScint, a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer, and NMP22 BladderChek, a point-of-care test that aids in the diagnosis of bladder cancer. Cytogen has also developed Quadramet, a skeletal targeting therapeutic radiopharmaceutical for the relief of bone pain in prostate and other types of cancer, for which it receives royalties on product sales through Berlex Laboratories, which markets the product in the United States. The Company's pipeline is comprised of product candidates at various stages of clinical development, including fully human monoclonal antibodies and cancer vaccines based on PSMA (prostate-specific membrane antigen) technology, which it exclusively licensed from Memorial Sloan-Kettering Cancer Center.
